Earnings ·
Emergent BioSolutions Inc. reported second quarter 2026 total revenues of $234.3 million, a 66% increase…
EBSEmergent BioSolutions Inc.
Emergent BioSolutions Inc. reported second quarter 2026 total revenues of $234.3 million, a 66% increase year-over-year, driven by accelerated U.S. government contract modifications for ACAM2000 and BAT products. The company posted a net loss of $180.2 million due to a $191.3 million non-cash impairment charge related to its NARCAN asset group, while adjusted EBITDA reached $96.5 million. Management announced a restructuring plan targeting approximately $40 million in annualized savings through the elimination of roughly 93 employee positions and the closure of wet laboratories in Gaithersburg, Maryland, with estimated charges of $10 million to $11.5 million expected in the second half of 2026. Concurrently, Chief Medical Officer Simon Lowry is departing effective August 19, 2026, and Stephanie Duatschek has been appointed Executive Vice President, Chief Growth Officer. The company revised its full-year 2026 revenue guidance downward to $645–$675 million from a previous range of $720–$760 million. Emergent BioSolutions operates in the biopharmaceutical industry, developing and manufacturing medical countermeasures for biodefense and commercial opioid overdose treatments.